di Reumatologia, Società Italiana, trans. 2026. “PO:03:033 | Low Uveitis Rates in Patients With Axial Spondyloarthritis or Psoriatic Arthritis Treated With Bimekizumab: Long-Term Results from Phase 2b 3 Trials: Irene E Van Der Horst-Bruinsma1, Matthew A Brown2, Floris A Van Gaalen3, Nigil Haroon4, Lianne S Gensler5, Alexander Marten6, Myriam Manente7, George Stojan8, Thomas Vaux9, Katy White9, Atul Deodhar10, Nicola Boffini11, Martin Rudwaleit12 | 1Department of Rheumatology, Radboud University Medical Centre Nijmegen, The Netherlands; 2Genomics England London, United Kingdom; 3Department of Rheumatology, Leiden University Medical Center Leiden, The Netherlands; 4Department of Medicine Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto Toronto, Canada; 5Department of Medicine Rheumatology, University of California San Francisco, USA; 6UCB Monheim Am Rhein Germany; 7UCB Braine-LAlleud, Belgium; 8UCB Atlanta, USA; 9UCB Slough, United Kingdom; 10Division of Arthritis and Rheumatic Diseases, Oregon Health and Science University Portland, USA; 11IRCCS Ospedale San Raffaele Milan, Italy; 12Klinikum Bielefeld, University of Bielefeld, Bielefeld, Germany”. Reumatismo 77 (s1). https://doi.org/10.4081/reumatismo.2025.2289.